Effect of alendronate on bone-specific alkaline phosphatase on periodontal bone loss in rats

Archives of Oral Biology

Volumn 57, Issue 11, 2012, Pages 1537-1544

  Goes, Paula ^a   Melo, Iracema M ^a   Dutra, Caio S ^a   Lima, Ana Patrícia S ^a   Lima, Vilma ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

Author keywords

Alendronate; Alveolar bone loss; Bone specific alkaline phosphatase; Inflammation

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BONE DENSITY CONSERVATION AGENT; SODIUM CHLORIDE;

ALVEOLAR BONE LOSS; ANALYSIS OF VARIANCE; ANIMAL; ARTICLE; BLOOD; CYTOLOGY; DRUG EFFECT; ENZYMOLOGY; JAW; JAW DISEASE; MALE; OSTEOCLAST; PATHOLOGY; PATHOPHYSIOLOGY; PERIODONTITIS; RAT; WISTAR RAT;

ALENDRONATE; ALKALINE PHOSPHATASE; ALVEOLAR BONE LOSS; ALVEOLAR PROCESS; ANALYSIS OF VARIANCE; ANIMALS; BONE DENSITY CONSERVATION AGENTS; MALE; MAXILLARY DISEASES; OSTEOCLASTS; PERIODONTITIS; RATS; RATS, WISTAR; SODIUM CHLORIDE;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 84869089082     PISSN: 00039969     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.archoralbio.2012.07.007     Document Type: Article

References (34)

1. W.V. Giannobile Host-response therapeutics for periodontal diseases Journal of Periodontology 79 Suppl. 8 2008 1592 1600
2. D.L. Cochran Inflammation and bone loss in periodontal disease Journal of Periodontology 79 Suppl. 8 2008 1569 1576
3. K. Vaananen Mechanism of osteoclast mediated bone resorption - rationale for the design of new therapeutics Advanced Drug Delivery Reviews 57 7 2005 959 971 (Pubitemid 40692288)
4. R.G. Russell Bisphosphonates: mode of action and pharmacology Pediatrics 119 Suppl. 2 2007 150 162
5. D.B. Kimmel Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates Journal of Dental Research 86 11 2007 1022 1033
6. M.P. Whyte Physiological role of alkaline phosphatase explored in hypophosphatasia Annals of the New York Academy of Sciences 1192 2010 190 200
7. V. Lima, F.D.P. Vidal, F.A.C. Rocha, G.A.C. Brito, and R.A. Ribeiro Effects of TNF-α inhibitors pentoxifylline and thalidomide on alveolar bone loss in short-term experimental periodontal disease in rats Journal of Periodontology 75 1 2004 162 168 (Pubitemid 38312781)
8. P. Goes, A.P.S. Lima, I.M. Melo, R.O. Rego, and V. Lima Effect of atorvastatin on ligature-induced periodontitis in Wistar rats: radiographic and macroscopic analysis Brazilian Dental Journal 21 3 2010 193 198
9. V. Lima, M.M. Bezerra, V.B.M. Alencar, F.D. Vidal, F.A. da Rocha, and G.A. de Castro Brito Effects of chlorpromazine on alveolar bone loss in experimental periodontal disease in rats European Journal of Oral Sciences 108 2 2000 123 129
10. D.W. Moss, and L.G. Whitby A simplified heat-inactivation method for investigating alkaline phosphatase isoenzymes in serum Clinica Chimica Acta 61 1 1975 63 71
11. J.H. Lin, D.E. Duggan, I.W. Chen, and R.L. Ellisworth Physiological disposition of alendronate, a potent antiosteolytic bisphosphonate, in laboratory animals Drug Metabolism and Disposition 19 1991 926 932
12. Y. Azuma, H. Sato, Y. Oue, K. Okabe, T. Ohta, and M. Tsuchimoto Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models Bone 16 2 1995 235 245
13. R.G. Russell Bisphosphonates: the first 40 years Bone 49 1 2011 2 19
14. M.J. Rogers, J.C. Crockett, F.P. Coxon, and J. Mönkkönen Biochemical and molecular mechanisms of action of bisphosphonates Bone 49 1 2011 34 41
15. M. Balcerzak, E. Hamade, L. Zhang, S. Pikula, G. Azzar, and J. Radisson The roles of annexins and alkaline phosphatase in mineralization process Acta Biochimica Polonica 50 4 2003 1019 1038 (Pubitemid 38608833)
16. R.A. Anderson, W.F. Bosron, F.S. Kennedy, and B.L. Vallee Role of magnesium in Escherichia coli alkaline phosphatase Proceedings of the National Academy of Sciences of the United States of America 72 8 1975 2989 2993
17. K. Still, R.J. Phipps, and A. Scutt Effects of risedronate, alendronate, and etidronate on the viability and activity of rat bone marrow stromal cells in vitro Calcified Tissue International 72 2 2003 143 150 (Pubitemid 36919534)
18. D.N. Vaisman, A.D. McCarthy, and A.M. Cortizo Bone-specific alkaline phosphatase activity is inhibited by bisphosphonates: role of divalent cations Biological Trace Element Research 104 2 2005 131 140 (Pubitemid 41411053)
19. P.M. Duarte, D.R. de Assis, M.Z. Casati, A.W. Sallum, E.A. Sallum, and F.H. Nociti Jr. Alendronate may protect against increased periodontitis-related bone loss in estrogen-deficient rats Journal of Periodontology 75 9 2004 1196 1202 (Pubitemid 39419717)
20. A.M. Menezes, F.A. Rocha, H.V. Chaves, C.B. Carvalho, R.A. Ribeiro, and G.A. Brito Effect of sodium alendronate on alveolar bone resorption in experimental periodontitis in rats Journal of Periodontology 76 11 2005 1901 1909 (Pubitemid 41748979)
21. S.E. Papapoulos Bisphosphonate actions: physical chemistry revisited Bone 38 5 2006 613 616
22. R.G. Russell, N.B. Watts, F.H. Ebetino, and M.J. Rogers Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy Osteoporosis International 19 6 2008 733 759
23. S.P. Luckman, D.E. Hughes, F.P. Coxon, R. Graham, G. Russell, and M.J. Rogers Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras Journal of Bone and Mineral Research 13 4 1998 581 589 (Pubitemid 28163009)
24. A. Alakangas, K. Selander, M. Mulari, J. Halleen, P. Lehenkari, and J. Mönkkönen Alendronate disturbs vesicular trafficking in osteoclasts Calcified Tissue International 70 1 2002 40 47 (Pubitemid 36934735)
25. N.J. Pavlos, J. Xu, D. Riedel, J.S. Yeoh, S.L. Teitelbaum, and J.M. Papadimitriou Rab3D regulates a novel vesicular trafficking pathway that is required for osteoclastic bone resorption Molecular and Cellular Biology 25 12 2005 5253 5269 (Pubitemid 40781122)
26. J.E. Fisher, M.J. Rogers, J.M. Halasy, S.P. Luckman, D.E. Hughes, and P.J. Masarachia Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro Proceedings of the National Academy of Sciences of the United States of America 96 1 1999 133 138 (Pubitemid 29036065)
27. N. Giuliani, M. Pedrazzoni, G. Passeri, and G. Girasole Bisphosphonates inhibit IL-6 production by human osteoblast-like cells Scandinavian Journal of Rheumatology 27 1 1998 38 41 (Pubitemid 28116468)
28. N. Makkonen, A. Salminen, M.J. Rogers, J.C. Frith, A. Urtti, and E. Azhayeva Contrasting effects of alendronate and clodronate on RAW 264 macrophages: the role of a bisphosphonate metabolite European Journal of Pharmaceutical Sciences 8 2 1999 109 118 (Pubitemid 29189156)
29. J. Mönkkönen, J. Similä, and M.J. Rogers Effects of tiludronate and ibandronate on the secretion of proinflammatory cytokines and nitric oxide from macrophages in vitro Life Sciences 62 8 1998 PL95 PL102
30. H. Takayanagi Inflammatory bone destruction and osteoimmunology Journal of Periodontal Research 40 4 2005 287 293 (Pubitemid 40977302)
31. I. Lambrinoudaki, G. Christodoulakos, and D. Botsis Bisphosphonates Annals of the New York Academy of Sciences 1092 2006 397 402 (Pubitemid 47092356)
32. F. Atamaz, S. Hepguler, M. Akyildiz, Z. Karasu, and M. Kilic Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation Osteoporosis International 17 6 2006 942 949 (Pubitemid 43781510)
33. C.O. Zein, R.A. Jorgensen, B. Clarke, D.E. Wenger, J.C. Keach, and P. Angulo Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial Hepatology 42 4 2005 762 771 (Pubitemid 41401113)
34. D.P. O'Doherty, E.V. McCloskey, S. Vasikaran, S. Khan, and J.A. Kanis The effects of intravenous alendronate in Paget's disease of bone Journal of Bone and Mineral Research 10 7 1995 1094 1100